T cell-dependent B cell hyperactivity in primary Sjögren's syndrome:Biomarker and target for treatment by Verstappen, Gwenny
  
 University of Groningen
T cell-dependent B cell hyperactivity in primary Sjögren's syndrome
Verstappen, Gwenny
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2018
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Verstappen, G. (2018). T cell-dependent B cell hyperactivity in primary Sjögren's syndrome: Biomarker and
target for treatment. [Groningen]: University of Groningen.
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 12-11-2019
 T FOLLICULAR REGULATORY 
CELLS FROM PATIENTS 
WITH PRIMARY SJÖGREN’S 
SYNDROME EXPRESS 
DECREASED LEVELS OF CTLA-4
3a
Gwenny M. Verstappen1 
Odilia B.J. Corneth2
Janneke Terpstra1 
Rudi W. Hendriks2 
Arjan Vissink3 
Hendrika Bootsma1
Frans G.M. Kroese1 
1Department of Rheumatology and Clinical Immunology, University of Groningen, 
University Medical Center Groningen, The Netherlands; 
2Department of Pulmonary Medicine, Erasmus MC, Rotterdam, The Netherlands; 
3Department of Oral and Maxillofacial Surgery, University of Groningen, 
University Medical Center Groningen, The Netherlands.
Work in progress
48 | CHAPTER 3a
ABSTRACT
Objective
Humoral immune responses rely to a large extent on T follicular helper (Tfh) cells. 
T follicular regulatory (Tfr) cells are important regulators of Tfh cells. Proportions of 
circulating Tfh (cTfh) cells are increased in primary Sjögren’s syndrome (pSS) patients 
compared with healthy controls (HCs). Tfh cells probably play a critical role in the 
enhanced activation of B cells in pSS. This study aimed to assess the frequency and 
phenotype of cTfh cells and circulating Tfr (cTfr) cells in pSS, as well as their relation to B 
cell activity and systemic disease activity. 
Methods
Sixty-eight pSS patients (66 female, mean age 50) classified according to the ACR-EULAR 
criteria and 24 HCs (23 female, mean age 43) were included. Cryopreserved peripheral 
blood mononuclear cells were analyzed by flow cytometry to assess the frequency of 
cTfh cells (CD45RA-FoxP3-CXCR5+PD-1+) and cTfr cells (CD45RA-FoxP3+CXCR5+PD-1+). 
Median expression levels of CTLA-4 per cell were also measured. 
Results
Frequencies of both cTfh cells and cTfr cells were elevated in pSS patients compared with 
HCs (P<0.001). Circulating Tfr cells were even more increased than cTfh cells, resulting 
in significantly higher cTfr/cTfh ratios in pSS (P<0.001). Frequencies of cTfh and cTfr cells 
correlated positively with serum levels of IgG and CXCL13, and systemic disease activity. 
In pSS patients, expression levels of CTLA-4 in cTfr cells were significantly decreased 
compared with HCs (P<0.001). Lower expression levels of CTLA-4 in cTfr cells tended to 
be associated with an increase in cTfh cells (ρ=-0.382, P=0.07). 
Conclusion
The cTfr/cTfh ratio is increased in pSS patients and frequencies of both subsets correlate 
with measures of B cell activity and systemic disease activity. Circulating Tfr cells from 
pSS patients express lower levels of CTLA-4, suggesting that despite their increased 
frequencies, their ability to suppress is impaired. A reduced suppressive capacity of Tfr 
cells may contribute to the expansion of Tfh cells and consequently to B cell hyperactivity 
in pSS.
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INTRODUCTION
Primary Sjögren’s syndrome (pSS) is a systemic autoimmune disease characterized 
by lymphocytic infiltration of salivary and lacrimal glands. B cell hyperactivity is a key 
feature of pSS pathogenesis, and is, among others, reflected by elevated serum IgG 
levels [1]. T follicular helper (Tfh) cells, an effector subset of CD4+ T cells, probably play 
a critical role in the enhanced activation of B cells. An important mechanism of B cell 
help by Tfh cells is the production of IL-21. This cytokine promotes B cell proliferation 
and differentiation towards plasma cells [2]. Costimulation and IL-21 production by Tfh 
cells are also crucial for somatic hypermutation, affinity maturation and class switch 
recombination of B cells within germinal centers (GC) [3]. 
 Tfh cell-mediated B cell help is naturally regulated by T follicular regulatory (Tfr) cells. 
Tfr cells are a specialized subset of regulatory T (Treg) cells and are able to suppress 
both Tfh cells and B cells within the GC [4–6]. In particular the ratio between Tfh cells 
and Tfr cells seems to control the magnitude of the antibody response [7]. An important 
mode of suppression by Treg cells is through the expression of cytotoxic T-lymphocyte-
associated protein 4 (CTLA-4). This inhibitory receptor is even more highly expressed on 
Tfr cells [5,8,9]. Possible mechanisms of suppression by Treg cells through CTLA-4 are I) 
physical sequestering of CD80/86 on antigen-presenting cells (APC), hereby attenuating 
CD28 signaling and T cell activation, II) transendocytosis of CD80/86 ligands upon 
interaction with APCs, and III) intrinsic competition with CD28 for CD80/86 binding at 
the immune synapse [10]. 
 While several studies have shown that proportions of circulating Tfh (cTfh) cells are 
increased in pSS patients compared with healthy controls (HCs) [11–15], the prevalence 
of cTfr cells in pSS is rather unexplored. Circulating cTfh and cTfr cells are thought to 
function as a memory pool to enable fast and strong, but controlled responses upon 
antigen re-encounter, although the suppressive capacity of circulating Tfr (cTfr) cells 
seems lower compared to Tfr cells in the GC [16]. Changes in proportions of Tfr cells and 
expression of inhibitory receptors, such as CTLA-4, may affect Tfh cell formation and 
function, as well as B cell responses. The aim of this study was to assess the frequency 
and phenotype of cTfr cells and cTfh cells in pSS. Furthermore, the relation between 
cTfr and cTfh cell frequencies, B cell activity, and systemic disease activity were studied. 
We found that cTfr cells were expanded in pSS patients, even to a larger extent than 
cTfh cells. The frequency of cTfr cells correlated positively with serum levels of IgG and 
CXCL13, and with systemic disease activity. Finally, we observed that circulating Treg 
cells, and in particular cTfr cells, from pSS patients express decreased levels of CTLA-4.
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PATIENTS AND METHODS
Study population
Twenty-four pSS patients (23 female, mean age 44 years) and 24 sex- and age-matched 
HCs (23 female, mean age 43 years) were included. All pSS patients participated in a 
previously reported, open-label re-treatment study with rituximab [17]. Twenty-four 
patients of this cohort were analyzed in the current study; 4 patients were not included 
because of unavailability of stored peripheral blood mononuclear cell (PBMC) samples 
(n=3) or serum sickness-like manifestations after the first dose of RTX (n=1). Patients 
were included at least one year after the last rituximab infusion, after reappearance of 
circulating B cells to baseline levels, and recurrence of symptoms. Only baseline samples 
before start of re-treatment were included in the current study. Characteristics of the 
study population have been described previously [14,18]. All patients retrospectively 
fulfilled 2016 ACR-EULAR criteria for pSS [19]. In addition, samples of 44 recently 
diagnosed, biologic treatment-naive pSS patients, included in an inception cohort, were 
analyzed (43 female, mean age 53 years). These patients prospectively fulfilled 2016 
ACR-EULAR criteria for pSS. 
 For all patients included in the current study, systemic disease activity was 
prospectively assessed by the ESSDAI and Clinical ESSDAI (ESSDAI without inclusion of 
the biological domain) [20,21]. All patients and HCs provided written informed consent. 
The study was approved by the Medical Ethics Committee of the University Medical 
Center Groningen (METc2008.179/METc2013.066). 
Flow cytometry analysis
Cryopreserved PBMC samples were thawed and of each sample two million cells were 
fluorescently labeled for immunophenotyping of CD4+ T cells by flow cytometry. A 
previously reported panel of antibodies was used [14], with addition of anti-human 
CTLA-4-BV421 (clone BNI3, BD Biosciences) for the 24 baseline samples of the rituximab 
cohort and HCs. Both membrane-bound and intracellular CTLA-4 expression was 
measured, because it is highly endocytic, resulting in approximately 90% of CTLA-
4 being intracellular [10]. The Foxp3 transcription factor fixation/permeabilization 
concentrate and diluent solutions (eBioscience) were used for staining of CTLA-4 (and 
FoxP3).
 Circulating Tfh cells were defined as CD4+CD45RA-FoxP3-CXCR5+PD-1+, cTfr cells as 
CD4+CD45RA-FoxP3+CXCR5+PD-1+ and peripheral Treg (pTreg) cells as CD4+CD45RA-
FoxP3+CXCR5- cells. Median expression levels per cell of CTLA-4 in cTfr cells and 
pTreg cells were measured by median fluorescence intensity (MFI). Flow cytometric 
measurements were performed on a FACS-LSRII flow cytometer (Becton Dickinson) and 
data were analyzed using FlowJo software (Tree Star).
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Analysis of CXCL13 levels in serum
In patients from the inception cohort, serum levels of CXCL13 were measured by an 
enzyme-linked immunosorbent assay (ELISA) using the DuoSet ELISA Human CXCL13 
development system (R&D systems), according to the manufacturer’s protocol.
Statistical analysis
Statistical analyses for comparisons between pSS patients and HCs were performed 
using Mann–Whitney U test. Correlations were evaluated with Spearman’s Rho tests. 
Two-tailed P values <0.05 were considered statistically significant.
RESULTS
Frequency and phenotype of cTfh cells and cTfr cells in pSS
Immunophenotyping of CD4+ T cells revealed that pSS patients presented with higher 
frequencies of circulating cTfh cells, as well as cTfr cells, compared with HCs (Figure 1A 
and 1B; P<0.001). Circulating Tfr cells were relatively further increased than cTfh cells, 
resulting in significantly higher cTfr/cTfh ratios in pSS patients, compared with HCs 
(Figure 1C; P<0.001). Frequencies of cTfh cells and cTfr cells were comparable between 
pSS patients from the rituximab cohort and the inception cohort, indicating that 

















































FIGURE 1 | Frequencies of cTfh cells, cTfr cells and the cTfr/cTfh ratio in pSS patients and healthy 
controls. Within the CD4+ T-cell compartment, frequencies of (A) cTfh cells (CD45RA-FoxP3-CXCR5+PD-1+) 
and (B) cTfr cells (CD4+CD45RA-FoxP3+CXCR5+PD-1+) were assessed and the cTfr/cTfh ratio (C) was calculated. 
Baseline data from pSS patients in the rituximab group (n=24) and data from the inception cohort (n=44) 
were combined. HC: healthy control. Horizontal lines indicate the median. P-values were calculated using the 
nonparametric Mann-Whitney U-test.
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To investigate the migratory potential of circulating cTfh cells and cTfr cells to inflamed 
tissue in pSS, expression of CXCR3 and CCR6 was measured. We found larger proportions 
of CXCR3-expressing cTfh and cTfr cells in pSS patients compared with HCs (Figure 2). 
The CXCR3+CCR6- phenotype, similar to Th1 cells [22], was predominant in pSS, both for 
cTfh cells (median 67%) and cTfr cells (median 44%). Frequencies of cTfh and cTfr cells 
with a CXCR3-CCR6+ phenotype, similar to Th17 cells, were not significantly different 






















































FIGURE 2  |  Chemokine receptor expression by cTfh and cTfr cells. Expression of CXCR3 and CCR6 
by circulating T follicular helper (cTfh) cells (A) and circulating T follicular regulatory (cTfr) cells (B) was 
measured in 24 pSS patients and 24 age- and sex-matched HCs. Bars indicate the median and interquartile 
range. P-values were calculated using the nonparametric Mann-Whitney U-test. *** P<0.001; ** P<0.01; ns: not 
significant (P≥0.05); HC: healthy control. 
Correlations between cTfh and cTfr cell frequencies, B cell hyperactivity 
and disease activity
Next, we assessed whether cTfh or cTfr cell frequencies were associated with serological 
markers of B cell hyperactivity and systemic disease activity in pSS patients. Both 
cTfh and cTfr cell frequencies correlated significantly with serum levels of IgG and 
immunoglobulin free light chains (Figure 3 and data not shown). Frequencies of both 
cell subsets also correlated significantly with serum levels of CXCL13 (Figure 3). CXCL13 
is an important chemokine for B cell homing to lymphoid follicles and is involved in 
ectopic lymphoid tissue formation in pSS [23,24]. On the other hand, the serum level 
of CXCL10, a biomarker that is associated with pSS[25], but not directly with B cell 
activity, was not significantly associated with cTfh or cTfr cell frequencies (data not 
shown). Together, these results indicate that increased frequencies of cTfh and cTfr cells 
are related to T cell-dependent B cell activity in pSS. Furthermore, these cell subsets 
correlated significantly with systemic disease activity, as measured by ESSDAI and 
clinESSDAI scores. (Figure 3). 
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FIGURE 3 | Correlations between cTfh and cTfr cell frequencies, signs of B cell hyperactivity and 
disease activity in pSS. Frequencies of (A) circulating T follicular helper (cTfh) cells and (B) circulating T 
follicular regulatory (cTfr) cells were correlated with serum levels of IgG and CXCL13, and ESSDAI scores. 
Baseline data from pSS patients in the rituximab group (n=24) and data from the inception cohort (n=44) were 
combined. Correlations were evaluated with Spearman’s correlation coefficient (ρ). ESSDAI: EULAR Sjögren’s 
syndrome disease activity index.
CTLA-4 expression by cTfr cells and other regulatory T cells in pSS
In addition to markers for phenotypic classification of human CD4+ T cells, median 
expression levels (median fluorescence intensity; MFI) of CTLA-4 were assessed. CTLA-4 
is important for immune suppression and alterations in CTLA-4 expression may affect 
immune homeostasis in pSS. We observed that levels of CTLA-4 in peripherally induced 
Treg (pTreg) cells as well as cTfr cells were significantly lower in pSS patients, compared 
with HCs (Figure 4C). The highest difference in CTLA-4 expression between pSS patients 
and HCs was seen in activated cTfr cells (CXCR5+PD-1+FoxP3high). These data suggest 
that the immune suppressive potential of pTreg cells, and in particular cTfr cells, is 
reduced in pSS patients. Since Tfr cells negatively regulate formation of Tfh cells [8], we 
correlated the MFI of CTLA-4 in cTfr cells to the frequency of cTfh cells. In patients with 
lower CTLA-4 expression levels, the frequency of cTfh cells tended to be higher (Figure 
4D). The correlation between CTLA-4 expression levels by activated (FoxP3hi) cTfr cells 
and frequencies of cTfh cells was even stronger (Spearman’s ρ=0.60, P=0.002). Together, 
these findings indicate that the suppressive capacity of cTfr cells is possibly reduced in 
pSS patients with decreased CTLA-4 expression.













FIGURE 4  |  Altered expression of CTLA-4 by regulatory T cells in pSS.  (A) Representative dot plot 
of CD45RA and FoxP3 expression in CD3+CD4+ cells from a pSS patient. Regulatory cells were subdivided 
into FoxP3lo (resting) and FoxP3hi (activated). (B) Representative histogram of CTLA-4 expression levels in 
diff erent CD4+ cell subsets from a pSS patient. (C) Median fl uorescence intensity (MFI) of CTLA-4 in resting 
and activated circulating pTreg cells (CD45RA-FoxP3+CXCR5-) and circulating T follicular regulatory (cTfr) cells 
(CD45RA-FoxP3+CXCR5+PD-1+). Data from 24 pSS patients and 24 healthy controls (HC) are displayed. P-values 
were calculated using the nonparametric Mann-Whitney U-test. Bars indicate the median and interquartile 
range. (D) Correlation between CTLA-4 expression levels by cTfr cells and frequencies of circulating T follicular 
helper (cTfh) cells, evaluated with Spearman’s correlation coeffi  cient (ρ). *** P<0.001; ** P<0.01. 
DISCUSSION
Tfh cells are elevated in the infl amed salivary glands and peripheral blood of pSS 
patients and are likely involved in the establishment of T cell-dependent B cell 
hyperactivity [14,15,26,27]. Tfr cells are important regulators of Tfh cell proliferation and 
B cell activation [28]. This study shows that not only cTfh, but also cTfr cell frequencies 
are increased in pSS patients compared with HCs, even to a larger extent than cTfh cells. 
A major proportion of cTfr cells in pSS patients expressed CXCR3, promoting CXCL10-
driven migration to infl amed tissues. Frequencies of cTfr cells correlated positively with 
serological markers of B cell activity and with systemic disease activity (i.e., ESSDAI 
and clinESSDAI scores). The increased frequencies of cTfr cells coincided with reduced 
expression of CTLA-4 by these cells, indicating that their suppressive potential is aff ected.
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 Recently, Fonseca et al. also showed that cTfr cells were increased in pSS patients 
[27,29]. In contrast to our study, they defined cTfr cells as CD4+CXCR5+Foxp3+ T cells, 
comprising both naive and memory T cells. They showed that the majority of cTfr cells 
were CD45RA+Foxp3lo resting, naive-like Treg cells [29]. These cells were able to suppress 
effector T cell proliferation, but lacked full B cell-suppressive capacity [29]. The authors 
suggested that the increase in cTfr cells could be a result of ongoing T cell activation 
in secondary lymphoid organs, leading to an increased output of cTfr (and cTfh) cells. 
In our study, cTfr cells were defined as CD4+CD45RA-FoxP3+CXCR5+PD-1+ T-cells, hereby 
selecting the smaller proportion of antigen-experienced, memory-like cells. In mice, 
these memory-like cTfr cells were shown to persist in the circulation for (at least) 30 
days, with the capacity to home to GCs after T cell reactivation [16]. These memory-like 
cTfr cells are therefore likely also the cells that migrate to the inflamed glandular tissues.
As a result of a greater rise in cTfr cells compared with cTfh cells, the cTfr/cTfh ratio is 
increased in pSS patients. In B cell follicles, a higher Tfr/Tfh ratio negatively regulates 
antibody responses [30]. However, immune responses are clearly not sufficiently 
suppressed in pSS. CTLA-4 is an important receptor for immune suppression by Treg 
cells. We found that expression levels of CTLA-4 are decreased in circulating pTreg cells, 
including cTfr cells, from pSS patients compared with HCs. As CTLA-4 reduces availability 
of CD80/86 on APCs [8], lower CTLA-4 levels may result in less efficient suppression 
of Tfh cell expansion and consequently increased B cell activity. Consistent with this 
notion, we observed a reverse correlation between cTfh cell frequencies and CTLA-4 
expression levels by cTfr cells. 
 Lower expression of CTLA-4 by Treg cells may not only affect proliferation of effector 
cells, like Tfh cells, but also proliferation of the Treg population itself can be enhanced 
[31,32]. In line with this notion, in the experimental autoimmune encephalomyelitis 
(EAE) mouse model, CTLA-4 deletion in Treg cells from adult mice resulted in expansion 
of effector T cells as well as Treg cells. Interestingly, we observed previously that 
frequencies of pTreg cells are also increased in peripheral blood of pSS patients [15]. The 
work presented here suggest that lower CTLA-4 levels may contribute to this expanded 
pool of pTregs. The implications of higher pTreg and cTfr cell frequencies for immune 
suppression and disease activity in pSS still need to be elucidated. Furthermore, the 
origin of these cell subsets remains controversial. A recent study in mice showed that 
Tfr cells could be derived from either FoxP3+ or FoxP3- precursor cells [33]. This study 
also showed that Tfr cells can be specific for self-antigen as well as foreign (immunized) 
antigen. However, another study in mice showed that Tfr cells were not specific for the 
immunized antigen, and instead expressed a TCR repertoire closely resembling that of 
thymus-derived natural Treg cells [34]. Because natural Treg cells have a TCR repertoire 
that is skewed towards self-antigen recognition [35], the latter study suggest that 
Tfr cells are important for the suppression of autoimmune responses. Whether the 
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expanded cTfr cell population in pSS patients recognizes mainly self-antigens or foreign 
antigens remains unknown and needs further investigation. 
 In summary, the expansion of cTfr cells in pSS is associated with increased B cell 
activity as well as systemic disease activity. Apparently, these cells do not exhibit (full) 
suppressive function and fail to control B cell responses once they are recruited to 
secondary lymphoid organs and/or ectopic lymphoid tissue in the inflamed glands. 
Although lower CTLA-4 expression is suggestive of lower suppressive potential, the 
functional capacity of memory-like cTfr cells needs to be investigated to confirm this 
assumption. Novel insights into the role of cTfr cells in pSS pathogenesis may lead to 
development of new therapies to enhance or mimic suppressive function of these cells 
and attenuate B cell activity. In addition, therapies that reduce the elevated levels of 
cTfh and pTreg cells in pSS patients, as we have shown for abatacept [15], may (partially) 
restore the disturbed immune homeostasis in this disease.
DECREASED CTLA-4 EXPRESSION BY TFR CELLS | 57
3a
REFERENCES
1  Kroese FG, Abdulahad WH, Haacke E, et al. B-cell hyperactivity in primary Sjogren’s syndrome. 
Expert Rev Clin Immunol 2014;10:483–99.
2  Moens L, Tangye SG. Cytokine-Mediated Regulation of Plasma Cell Generation: IL-21 Takes 
Center Stage. Front Immunol 2014;5:65.
3  Crotty S. T Follicular Helper Cell Differentiation, Function, and Roles in Disease. Immunity 
2014;41:529–42.
4  Chung Y, Tanaka S, Chu F, et al. Follicular regulatory T cells expressing Foxp3 and Bcl-6 
suppress germinal center reactions. Nat Med 2011;17:983–8.
5  Linterman MA, Pierson W, Lee SK, et al. Foxp3+ follicular regulatory T cells control the germinal 
center response. Nat Med 2011;17:975–82.
6  Wollenberg I, Agua-Doce A, Hernandez A, et al. Regulation of the Germinal Center Reaction 
by Foxp3+ Follicular Regulatory T Cells. J Immunol 2011;187:4553–60.
7  Sage PT, Sharpe AH. T follicular regulatory cells in the regulation of B cell responses. Trends 
Immunol 2015;36:410–8.
8  Wing JB, Ise W, Kurosaki T, et al. Regulatory T cells control antigen-specific expansion of 
Tfh cell number and humoral immune responses via the coreceptor CTLA-4. Immunity 
2014;41:1013–25.
9  Sage PT, Paterson AM, Lovitch SB, et al. The coinhibitory receptor CTLA-4 controls B cell 
responses by modulating T follicular helper, T follicular regulatory, and T regulatory cells. 
Immunity 2014;41:1026–39.
10  Walker LSK, Sansom DM. Confusing signals: Recent progress in CTLA-4 biology. Trends 
Immunol 2015;36:63–70.
11  Simpson N, Gatenby PA, Wilson A, et al. Expansion of circulating T cells resembling follicular 
helper T cells is a fixed phenotype that identifies a subset of severe systemic lupus 
erythematosus. Arthritis Rheum 2010;62:234–44.
12  Liu R, Su D, Zhou M, et al. Umbilical cord mesenchymal stem cells inhibit the differentiation of 
circulating T follicular helper cells in patients with primary Sjogren’s syndrome through the 
secretion of indoleamine 2,3-dioxygenase. Rheumatology (Oxford) 2015;54:332–42.
13  Szabo K, Papp G, Barath S, et al. Follicular helper T cells may play an important role in the 
severity of primary Sjogren’s syndrome. Clin Immunol 2013;147:95–104.
14  Verstappen GM, Kroese FGM, Meiners PM, et al. B cell depletion therapy normalizes circulating 
follicular TH cells in primary Sjögren syndrome. J Rheumatol 2017;44:49–58.
15  Verstappen GM, Meiners PM, Corneth OBJ, et al. Attenuation of Follicular Helper T Cell-
Dependent B Cell Hyperactivity by Abatacept Treatment in Primary Sjögren’s Syndrome. 
Arthritis Rheumatol 2017;69:1850–61.
16  Sage PT, Alvarez D, Godec J, et al. Circulating T follicular regulatory and helper cells have 
memory-like properties. J Clin Invest 2014;124:5191–204.
17  Meijer JM, Meiners PM, Vissink A, et al. Effectiveness of rituximab treatment in primary 
Sjögren’s syndrome: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 
2010;62:960–8.
18  Meiners PM, Arends S, Meijer JM, et al. Efficacy of retreatment with rituximab in patients with 
primary Sjogren’s syndrome. Clin Exp Rheumatol 2015;33:443–4.
58 | CHAPTER 3a
19  Shiboski CH, Shiboski SC, Seror R, et al. 2016 American College of Rheumatology/European 
League Against Rheumatism Classification Criteria for Primary Sjögren’s Syndrome: A 
Consensus and Data-Driven Methodology Involving Three International Patient Cohorts. 
Arthritis Rheumatol 2017;69:35–45.
20  Seror R, Ravaud P, Bowman SJ, et al. EULAR Sjogren’s syndrome disease activity index: 
development of a consensus systemic disease activity index for primary Sjogren’s syndrome. 
Ann Rheum Dis 2010;69:1103–9.
21  Seror R, Meiners P, Baron G, et al. Development of the ClinESSDAI: a clinical score without 
biological domain. A tool for biological studies. Ann Rheum Dis 2016;75:1945–50.
22  Rivino L, Messi M, Jarrossay D, et al. Chemokine receptor expression identifies Pre-T helper 
(Th)1, Pre-Th2, and nonpolarized cells among human CD4+ central memory T cells. J Exp Med 
2004;200:725–35.
23  Gunn MD, Ngo VN, Ansel KM, et al. A B-cell-homing chemokine made in lymphoid follicles 
activates Burkitt’s lymphoma receptor-1. Nature 1998;391:799–803.
24  Barone F, Bombardieri M, Manzo A, et al. Association of CXCL13 and CCL21 expression with 
the progressive organization of lymphoid-like structures in Sjogren’s syndrome. Arthritis 
Rheum 2005;52:1773–84.
25  Ogawa N, Ping L, Zhenjun L, et al. Involvement of the interferon-gamma-induced T cell-
attracting chemokines, interferon-gamma-inducible 10-kd protein (CXCL10) and monokine 
induced by interferon-gamma (CXCL9), in the salivary gland lesions of patients with Sjögren’s 
syndrome. Arthritis Rheum 2002;46:2730–41.
26  Pontarini E, Lucchesi D, Bombardieri M. Current views on the pathogenesis of Sjögren’s 
syndrome. Curr Opin Rheumatol 2018;30:215–21.
27  Fonseca VR, Romão VC, Agua-Doce A, et al. Blood T Follicular Regulatory Cells / T Follicular 
Helper Cells ratio Marks Ectopic Lymphoid Structure Formation and PD-1 + ICOS + T Follicular 
Helper Cells Indicate Disease Activity in Primary Sjögren’s Syndrome. Arthritis Rheumatol 
Published Online First: 23 January 2018.
28  Sage PT, Sharpe AH. T follicular regulatory cells. Immunol Rev 2016;271:246–59.
29  Fonseca VR, Agua-Doce A, Maceiras AR, et al. Human blood T fr cells are indicators of ongoing 
humoral activity not fully licensed with suppressive function. Sci Immunol 2017;2:eaan1487.
30  Sage PT, Francisco LM, Carman C V, et al. The receptor PD-1 controls follicular regulatory T 
cells in the lymph nodes and blood. Nat Immunol 2012;14:152–61.
31  Schubert D, Bode C, Kenefeck R, et al. Autosomal dominant immune dysregulation syndrome 
in humans with CTLA4 mutations. Nat Med 2014;20:1410–6.
32  Schmidt EM, Wang CJ, Ryan GA, et al. Ctla-4 controls regulatory T cell peripheral homeostasis 
and is required for suppression of pancreatic islet autoimmunity. J Immunol 2009;182:274–
82.
33  Aloulou M, Carr EJ, Gador M, et al. Follicular regulatory T cells can be specific for the 
immunizing antigen and derive from naive T cells. Nat Commun 2016;7:10579.
34  Maceiras AR, Almeida SCP, Mariotti-Ferrandiz E, et al. T follicular helper and T follicular 
regulatory cells have different TCR specificity. Nat Commun 2017;8:15067.
35  Hsieh C-S, Liang Y, Tyznik AJ, et al. Recognition of the peripheral self by naturally arising 
CD25+ CD4+ T cell receptors. Immunity 2004;21:267–77.


